| abstract |
The present invention relates to antibodies that specifically bind to components of the modified DNA synthesome in malignant cells. Such antibodies can be used, in particular, to diagnose, predict, and treat malignancy and in assays for screening cells, tissues, and body fluids for the presence of malignant phenotypes. Such antibodies can be used to identify sample components that have the ability to inhibit the malignant phenotype in cells by analyzing the ability to inhibit or prevent the function of the modified components of the DNA synthesome associated with the malignant phenotype. The presence of tumors to detect the presence of cancer as well as assess the patient's prognosis and disease status using readily available body fluids such as blood, plasma, lymph, pleural fluid, spinal fluid, saliva, phlegm, urine and semen Provides methods and kits for detecting minimally invasive and malicious conditions. By detecting the presence of components of the modified form of the DNA synthesome in body fluids, malignancy can be diagnosed and predicted. The disclosed methods and kits can be used as a diagnostic biomarker of malignancy as well as as a means of monitoring the progress and effectiveness of therapy. |